Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Argus Health
Fish and Richardson
Farmers Insurance
AstraZeneca

Generated: August 21, 2019

DrugPatentWatch Database Preview

RUZURGI Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

When do Ruzurgi patents expire, and what generic alternatives are available?

Ruzurgi is a drug marketed by Jacobus Pharm Co Inc and is included in one NDA.

The generic ingredient in RUZURGI is amifampridine. One supplier is listed for this compound. Additional details are available on the amifampridine profile page.

Summary for RUZURGI
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 1
DailyMed Link:RUZURGI at DailyMed
Drug patent expirations by year for RUZURGI
Generic Entry Opportunity Date for RUZURGI
Generic Entry Date for RUZURGI*:
Constraining patent/regulatory exclusivity:
TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN PATIENTS 6 TO LESS THAN 17 YEARS OF AGE
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for RUZURGI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jacobus Pharm Co Inc RUZURGI amifampridine TABLET;ORAL 209321-001 May 6, 2019 RX Yes Yes   Try a Free Trial   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
QuintilesIMS
Citi
Deloitte
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.